GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (NYSE:COR) » Definitions » COGS-to-Revenue
中文

Cencora (Cencora) COGS-to-Revenue : 0.97 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Cencora COGS-to-Revenue?

Cencora's Cost of Goods Sold for the three months ended in Dec. 2023 was $69,784 Mil. Its Revenue for the three months ended in Dec. 2023 was $72,253 Mil.

Cencora's COGS to Revenue for the three months ended in Dec. 2023 was 0.97.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cencora's Gross Margin % for the three months ended in Dec. 2023 was 3.42%.


Cencora COGS-to-Revenue Historical Data

The historical data trend for Cencora's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cencora COGS-to-Revenue Chart

Cencora Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.97 0.97 0.97 0.97 0.97

Cencora Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.96 0.97 0.97 0.97

Cencora COGS-to-Revenue Calculation

Cencora's COGS to Revenue for the fiscal year that ended in Sep. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=253213.918 / 262173.411
=0.97

Cencora's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=69784.021 / 72252.833
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cencora  (NYSE:COR) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cencora's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 69784.021 / 72252.833
=3.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Cencora COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cencora's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cencora (Cencora) Business Description

Traded in Other Exchanges
Address
1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Executives
Leslie E Donato officer: EVP & Chief Strategy Officer 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Elizabeth S Campbell officer: Executive Vice President 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Steven H Collis officer: President & CEO 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Lazarus Krikorian officer: Senior Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Silvana Battaglia officer: Executive Vice President 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Walgreens Boots Alliance, Inc. 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Gina Clark officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Werner Baumann director 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Lauren M Tyler director C/O ALLEGHANY CORPORATION, 1411 BROADWAY, 34TH FLOOR, NEW YORK NY 10018
Robert P. Mauch officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Redonda Miller director 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Lorence H. Kim director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Walgreens Boots Alliance Holdings Llc 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Lon R Greenberg director 460 NORTH GULPH ROAD, KING OF PRUSSIA PA 19406
John G. Chou officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087